CA2465186A1 — Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
Assigned to Sumitomo Pharma America Inc · Expires 2003-05-15 · 23y expired
What this patent protects
This invention relates to novel compositions of matter containing enantiomerically enriched (-)-desmethylcitalopram, (+)-didesmethylcitalopram , or (-)-didesmethylcitalopram or mixtures thereof in optimal ratios. Contrary to prior teachings, the enantiomerically enriched cita…
USPTO Abstract
This invention relates to novel compositions of matter containing enantiomerically enriched (-)-desmethylcitalopram, (+)-didesmethylcitalopram , or (-)-didesmethylcitalopram or mixtures thereof in optimal ratios. Contrary to prior teachings, the enantiomerically enriched citalopram metabolites disclosed herein possess potent serotonin reuptake inhibitory activity, with minimal inhibitory effects on the reuptake of other known monoamines, e.g., norepinephrine (NE) or dopamine (DA). The present invention also discloses methods for treating disorders, dysfunctions and diseases for which inhibiti on of serotonin reuptake is therapeutically beneficial. In particular, the present invention discloses a method for treating various forms of depressio n with pharmaceutical compositions described herein.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.